Artificial Blood Substitute Maker Raises $50 Million
Sangart Inc., a San Diego-based developer of an artificial blood substitute, has raised $50 million in additional Series F funding. This brings the round total to $100 million, and the company’s total venture capitalization to over $170 million. No investor information was disclosed, although the initial tranche was led by Leucadia National Corp.
13 March 2009•2 mins read
